Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and pyrotinib in HER2+ advanced gastric or GEJ adenocarcinoma
NCT05111444Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Fragment-Derived Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and pyrotinib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Fudan University. Status: unknown.
02
Drugs
camrelizumabpyrotinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05111444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05111444.